Tango Therapeutics, Inc. (TNGX) Operating Margin
- Operating margin · 12 months: Value -253.38%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -253.38% | Operating income / revenue. Period ending 2026-06-30. $-136.35M ÷ $53.81M × 100 ≈ -253.38% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -136.35M USD | Operating Income (Loss) |
| Revenue | 53.81M USD | |
| Cost of products and services | (m) | |
| Research and development | 133.65M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-136.35M | $53.81M | (m) | $133.65M | (m) | -253.38% |
| 2026-03-31 | $-117.53M | $56.99M | (m) | $129.26M | (m) | -206.22% |
| 2025-12-31 | $-111.29M | $62.38M | (m) | $132.16M | (m) | -178.39% |
| 2025-09-30 | $-110.33M | $66.50M | (m) | $134.00M | (m) | -165.91% |
| 2025-06-30 | $-157.28M | $24.30M | (m) | $136.45M | (m) | -647.37% |
| 2025-03-31 | $-145.87M | $40.99M | (m) | $142.29M | (m) | -355.87% |
| 2024-12-31 | $-145.59M | $42.07M | (m) | $143.92M | (m) | -346.09% |
| 2024-09-30 | $-139.70M | $43.38M | (m) | $141.32M | (m) | -322.01% |
| 2024-06-30 | $-132.45M | $42.51M | (m) | $135.21M | (m) | -311.57% |
| 2024-03-31 | $-126.14M | $37.23M | (m) | $125.22M | (m) | -338.80% |
| 2023-12-31 | $-114.17M | $36.53M | (m) | $115.20M | (m) | -312.57% |
| 2023-09-30 | $-109.73M | $37.51M | (m) | $112.95M | (m) | -292.55% |
| 2023-06-30 | $-114.02M | $33.70M | (m) | $114.55M | (m) | -338.40% |
| 2023-03-31 | $-115.98M | $24.87M | (m) | $109.61M | (m) | -466.37% |
| 2022-12-31 | $-111.07M | $24.86M | (m) | $105.91M | (m) | -446.79% |
| 2022-09-30 | $-102.49M | $24.16M | (m) | $98.45M | (m) | -424.12% |
| 2022-06-30 | $-92.13M | $24.03M | (m) | $91.63M | (m) | -383.38% |
| 2022-03-31 | $-71.49M | $36.41M | (m) | $86.97M | (m) | -196.32% |
| 2021-12-31 | $-58.19M | $37.04M | (m) | $77.64M | (m) | -157.09% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |